Completed Access to Information Requests

Follow:

  • RSS
  • Cite

    Cite

    APA

    Open Government - Government of Canada. (2017, December 10). Completed Access to Information Requests. Retrieved from http://open.canada.ca/en/search/ati?f%5B0%5D=ss_ati_organization_en%3AToronto%20Port%20Authority&amp%3Bamp%3Bati%5B0%5D=ss_ati_organization_en%3ACanada-Newfoundland%20and%20Labrador%20Offshore%20Petroleum%20Board&amp%3Bamp%3Bati%5B1%5D=ss_ati_organization_en%3ANatural%20Resources%20Canada&amp%3Bamp%3Bati%5B2%5D=ss_ati_organization_en%3AStatus%20of%20Women%20Canada&amp%3Bati%5B0%5D=ss_ati_organization_en%3AExport%20Development%20Canada&ati%5B0%5D=%3AAtlantic%20Canada%20Opportunities%20Agency&ati%5B1%5D=%3ACanadian%20Centre%20for%20Occupational%20Health%20and%20Safety&ati%5B2%5D=%3ADepartment%20of%20Justice%20Canada&ati%5B3%5D=%3AOffice%20of%20the%20Auditor%20General%20of%20Canada&ati%5B4%5D=ati_month_en%3ASeptember&ati%5B5%5D=ati_organization_en%3AFinancial%20Transactions%20and%20Reports%20Analysis%20Centre%20of%20Canada&ati%5B6%5D=ati_organization_en%3AHealth%20Canada&ati%5B7%5D=ati_organization_en%3AOffice%20of%20the%20Information%20Commissioner%20of%20Canada&ati%5B8%5D=ati_organization_en%3ASt.%20John%27s%20Port%20Authority&search_api_fulltext=&sort_by=year&sort_order=DESC&f%5B0%5D=ss_ati_organization_en%3AToronto%20Port%20Authority&page=2
    MLA

    “Completed Access to Information Requests.” Open Government - Government of Canada, 10 December 2017, http://open.canada.ca/en/search/ati?f%5B0%5D=ss_ati_organization_en%3AToronto%20Port%20Authority&amp%3Bamp%3Bati%5B0%5D=ss_ati_organization_en%3ACanada-Newfoundland%20and%20Labrador%20Offshore%20Petroleum%20Board&amp%3Bamp%3Bati%5B1%5D=ss_ati_organization_en%3ANatural%20Resources%20Canada&amp%3Bamp%3Bati%5B2%5D=ss_ati_organization_en%3AStatus%20of%20Women%20Canada&amp%3Bati%5B0%5D=ss_ati_organization_en%3AExport%20Development%20Canada&ati%5B0%5D=%3AAtlantic%20Canada%20Opportunities%20Agency&ati%5B1%5D=%3ACanadian%20Centre%20for%20Occupational%20Health%20and%20Safety&ati%5B2%5D=%3ADepartment%20of%20Justice%20Canada&ati%5B3%5D=%3AOffice%20of%20the%20Auditor%20General%20of%20Canada&ati%5B4%5D=ati_month_en%3ASeptember&ati%5B5%5D=ati_organization_en%3AFinancial%20Transactions%20and%20Reports%20Analysis%20Centre%20of%20Canada&ati%5B6%5D=ati_organization_en%3AHealth%20Canada&ati%5B7%5D=ati_organization_en%3AOffice%20of%20the%20Information%20Commissioner%20of%20Canada&ati%5B8%5D=ati_organization_en%3ASt.%20John%27s%20Port%20Authority&search_api_fulltext=&sort_by=year&sort_order=DESC&f%5B0%5D=ss_ati_organization_en%3AToronto%20Port%20Authority&page=2
    (Report an issue with citation)
About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA). For additional information, please see the “About Access to Information Requests” webpage.

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 391 record(s)

Req # A-2023-000365

All notice of allegation (NOA) filing dates as outlined under sections 5(2.1)(c)(ii), (iii), and (iv) of the Patented Medicines (Notice of Compliance) Regulations, as well as the date in which the NOA was responded to by the first person for the following drugs, between the specified companies. AstraZeneca v Mylan VIMOVO; Merck Sharp & Dohme v Pharmascience JANUVIA; Teva v Pharmascience COPAXONE; Bristol-Myers Squibb v Mylan Pharmaceuticals SUSTIVA; Pfizer v Mylan Pharmaceuticals CELEBREX; Valeant v Generic Partners GLUMETZA; Janssen v Apotex OPSUMIT; Janssen vSandoz OPSUMIT; Alcon v Cobalt Pharmaceuticals PATANOL; Apotex v Shire VYVANSE; Eli Lilly v Mylan Pharmaceuticals CIALIS; Eli Lilly v Apotex CIALIS; Hoffman-La Roche v Apotex VALCYTE; Les Laboratoires Servier v Apotex VIACORAM; Eli Lilly v Teva ALIMTA; Janssen v Celltrion Healthcare REMICADE; Bayer v Apotex YAZ; Bayer v Cobalt Pharmaceuticals YAZ; Astrazeneca v Mylan Pharmaceuticals ARIMIDEX; Novartis Pharmaceuticals v Cobalt Pharmaceuticals Company ACLASTA; Teva v Janssen VELCADE; Laboratoires Servier v Apotex DIAMICRON MR; VIIV Healthcare v Teva KIVEXA; Gilead Sciences v Apotex TRUVADA; Sunovion Pharmaceuticals v Taro Pharmaceuticals LATUDA; Allergan v Sandoz COMBIGAN; Novartis Pharmaceuticals v Teva ZOMETA CONCENTRATE; Bayer v Sandoz ADEMPAS; Bayer v. Dr. Reddy‘s Laboratories Xarelto; Biomarin Pharmaceutical v. Dr. Reddy’s Laboratories KUVAN; Pfizer v Apotex CELEBREX; Bristol-Myers Squibb v Pharmascience ELIQUIS; Bristol-Myers Squibb & Gilead Sciences v Teva ATRIPLA; Purdue Pharma v Collegium Pharmaceuticals OXYNEO; Genentech v Amgen HERCEPTIN; Hoffmann-La Roche v Sandoz ESBRIET; Alcon v Apotex TRAVATAN Z; Janssen v Apotex INVEGA SUSTENNA; Janssen v Teva INVEGA SUSTENNA; Bristol-myers Squibb v Teva REYATAZ; Novo Nordisk v Teva VICTOZA; Bristol-Myers Squibb v Apotex SPRYCEL; Eli Lilly v NuPharm ZYPREXA; Valeant v Cobalt Pharmaceuticals TIAZAC XC; Eli Lilly v Apotex ADCIRCA; Shire v Cobalt Pharmaceuticals Company ADDERALL XR; AstraZeneca v Teva SEROQUEL XR; Eli Lilly v Hospira Healthcare Corporation ALIMTA; Alcon v Apotex Pataday; Valeant v Apotex GLUMETZA; Novartis Pharmaceuticals v Mylan Pharmaceuticals EXELON; Bristol-Myers Squibb v Sandoz ELIQUIS; Bristol-Myers Squibb v. Apotex ELIQUIS; AstraZeneca v Sandoz ONGLYZA; AstraZeneca v Sandoz KOMBOGLYZE; Takeda v Mylan TECTA; Janssen v Actavis Pharma CONCERTA; Pfizer v. Apotex PRISTIQ; Janssen v Apotex ZYTIGA; Janssen v Apotex ZYTIGA; Janssen v Dr Reddys Laboratories ZYTIGA; Bristol-Myers Squibb v Dr. Reddys Laboratories Zytiga; Janssen v Pharmascience ZYTIGA; Eli Lilly v Mylan CIALIS; Allergan v Apotex ZYMAR; Janssen v Apotex PREZISTA; Allergan v Apotex ACTONEL DR.

Organization: Health Canada

214 page(s)
September 2023

Req # A-2023-000384

Drafts and finalized version of the report on Sex and Gender-Based Analysis Plus (SGBA Plus) in Medical Devices presented to the Director General of Medical Devices Directorate (MDD) by the Scientific Advisory Committee on Health Products for Women.

Organization: Health Canada

395 page(s)
September 2023

Req # A-2023-000441

The initial cover letter indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-06-23 for the medicinal ingredient Mesalazine. The Screening Acceptance Letter from Health Canada to the generic drug manufacturer confirming completion of screening of the Abbreviated New Drug Submission (ANDS) for Mesalazine which appears in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-06-23. The strength (s) and dosage form of any and all generic drugs in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-06-23 for the medicinal ingredient Mesalazine. The conditions and the reference product used for the bioequivalence study of any and all generic drugs in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-06-23 for the medicinal ingredient Mesalazine.

Organization: Health Canada

115 page(s)
September 2023

Req # A-2023-000442

The initial cover letter indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-06-23 for the medicinal ingredient Amphotericin B. The Screening Acceptance Letter from Health Canada to the generic drug manufacturer confirming completion of screening of the Abbreviated New Drug Submission (ANDS) for Amphotericin B which appears in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-06-23. The strength (s) and dosage form of any and all generic drugs in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-06-23 for the medicinal ingredient Amphotericin B. The conditions and the reference product used for the bioequivalence study of any and all generic drugs in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-06-23 for the medicinal ingredient Amphotericin B.

Organization: Health Canada

91 page(s)
September 2023

Req # A-2023-000507

Obtain all non-confidential documents for the following medical device licence application approved by Health Canada in 2016: Licence No.: 97381; Type: System; Device class: 2; Device first issue date 2016-07-27; Licence name: LUCAS 3 CHEST COMPRESSION SYSTEM.

Organization: Health Canada

66 page(s)
September 2023

Req # A-2023-000537

All correspondence between Health Canada and the College of Physicians and Surgeons of Ontario, and Health Canada (HC) and the Ontario College of Pharmacists (OPC) related to the use Ivermectin for COVID-19. Date range January 1 2020 to May 31 2023. Any Emails from February 2022 between Anne Anton Kumar a 'Compliance & Regulatory Operations Enforcer' and Ontario College of Pharmacy, and any emails from Ontario Provicial Police (OPP) Officer to OCP regarding potential fraud.

Organization: Health Canada

4 page(s)
September 2023

Req # A-2023-000570

With respect to the New Drug Submission for ABSORICA LD, portions of the New Drug Submission that relate to Sun Pharmaceuticals Industries Limited’s ownership, agreement, or contractual rights to the data in the Phase III study referenced in section “14.1 Clinical Trials by Indication".

Organization: Health Canada

0 page(s)
September 2023

Req # A-2023-000698

Techstar Real Estate Holdings Inc. Outstanding work orders, notices, violations, or infractions with respect to the Owner, the Affiliate, and/or the Property under the control or the authority of Health Canada.

Organization: Health Canada

0 page(s)
September 2023

Req # A-2023-000713

A copy of all information released as part of Freedom of Information (FOI) request number A-2016-00717, completed by your office around October 1, 2016.

Organization: Health Canada

4 page(s)
September 2023

Req # A-2023-000714

All information released as part of Freedom of Information (FOI) request number A-2011-01257, completed by your office around March 1, 2014.

Organization: Health Canada

0 page(s)
September 2023
Date modified: